About NeoFuse MPC (Prod 9445)
The proprietary technology being commercialised by Mesoblast enables efficient extraction, isolation and scale-up of mesenchymal-type adult stem cells called mesenchymal precursor cells (MPC). This technology relies on the identification of unique markers on the surface of the MPC to which monoclonal antibodies bind, enabling the extraction of MPC from the mixture of cells in their resident tissues. Mesoblast's MPC technology can generate both new bone and new blood vessels, enabling greater bone regeneration. There will be no immune reaction and no donor site, so no chronic pain. Implantation of MPC at the site of poorly-healing fractures is likely to be more effective in less time, while eliminating other complications of bone grafting.
OrthopaedicLIST.com is a list of products and services. Every effort is made to keep this listing as accurate and current as possible. Companies and individuals are encouraged to notify us of errors and omissions. We will respond to such messages of correction in a timely fashion, as our workload permits.
We are non-judgmental of products listed. We are not in the business of evaluating products. We have not evaluated these products. We make no representations as to the quality, effectiveness, suitability or appropriateness of any of the products listed.
As an important component of the service function of OrthopaedicLIST.com, some products continue to be listed that are no longer manufactured and may not be available. We will identify them as such when possible. This allows users to find special instruments and/or components for removal, modification, and/or revision of those products.